HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features

被引：0

作者：

Zare, Somaye ^{[1
]}

Lin, Leo ^{[1
]}

Alghamdi, Abrar G. ^{[2
]}

Roma, Andres ^{[2
]}

Dell'Aquila, Marie ^{[1
]}

Hasteh, Farnaz ^{[2
]}

Fadare, Oluwole ^{[1
]}

机构：

[1] UC San Diego Hlth, San Diego, CA USA

[2] Univ Calif San Diego, San Diego, CA 92103 USA

来源：

MODERN PATHOLOGY | 2018年 / 31卷

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

328

引用

页码：117 / 117

页数：1

共 50 条

[21] Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha
Islam M. Miligy
Cecily M. Quinn
Elena Provenzano
Abeer M. Shaaban
Caterina Marchiò
Michael S. Toss
Grace Gallagy
Ciara Murray
Janice Walshe
Ayaka Katayama
Karim Eldib
Nahla Badr
Bruce Tanchel
Rebecca Millican-Slater
Colin Purdie
Dave Purnell
Sarah E. Pinder
Ian O. Ellis
Andrew H. S. Lee
British Journal of Cancer, 2021, 124 : 1836 - 1842
[22] Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2:CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study
Ballard, Morgan
Toukatly, Mirna
Bean, Gregory
Jalikis, Florencia
Krings, Gregor
Schmidt, Rodney
Chen, Yunn-Yi
Dintzis, Suzanne
Troxell, Megan
West, Robert
Sibley, Richard
Allison, Kimberly
LABORATORY INVESTIGATION, 2018, 98 : 47 - 48
[23] Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study
Ballard, Morgan
Toukatly, Mirna
Bean, Gregory
Jalikis, Florencia
Krings, Gregor
Schmidt, Rodney
Chen, Yunn-Yi
Dintzis, Suzanne
Troxell, Megan
West, Robert
Sibley, Richard
Allison, Kimberly
MODERN PATHOLOGY, 2018, 31 : 47 - 48
[24] Utility of HER2 Immunohistochemistry in Clarifying HER2 Status in Breast Cancer with HER2:CEP17 Ratio <2 and Average >/=4.0 and <6.0 HER2 Signals per Tumor Cell by Fluorescence in-situ Hybridization (Focused Update Group 4)
Muller, Kristen
Marotti, Jonathan
Tafe, Laura
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 223 - 223
[25] Utility of HER2 Immunohistochemistry in Clarifying HER2 Status in Breast Cancer with HER2:CEP17 Ratio <2 and Average >/=4.0 and <6.0 HER2 Signals per Tumor Cell by Fluorescence in-situ Hybridization (Focused Update Group 4)
Muller, Kristen
Marotti, Jonathan
Tafe, Laura
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 223 - 223
[26] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
MODERN PATHOLOGY, 2018, 31 : 45 - 45
[27] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
LABORATORY INVESTIGATION, 2018, 98 : 45 - 45
[28] Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals /cell >6.0 by FISH; A Multi-Institutional Study
Ballard, Morgan
Toukatly, Mirna
Bean, Gregory
Jalikis, Florencia
Krings, Gregor
Schmidt, Rodney
Chen, Yunn-Yi
Rendi, Mara
Dintzis, Suzanne
Troxell, Megan
West, Robert
Sibley, Richard
Allison, Kimberly
LABORATORY INVESTIGATION, 2018, 98 : 48 - 48
[29] High HER2 signals and HER2/CEP17 ratio tumours achieve better responses in breast cancer
Exposito Afonso, I. J.
del Pino Sedeno, T.
Gonzalez Villa, I.
Loro Ferrer, J. F.
Cabrera Galvan, J. J.
VIRCHOWS ARCHIV, 2020, 477 : S45 - S46
[30] Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals/cell >6.0 by FISH; A Multi-Institutional Study
Ballard, Morgan
Toukatly, Mirna
Bean, Gregory
Jalikis, Florencia
Krings, Gregor
Schmidt, Rodney
Chen, Yunn-Yi
Rendi, Mara
Dintzis, Suzanne
Troxell, Megan
West, Robert
Sibley, Richard
Allison, Kimberly
MODERN PATHOLOGY, 2018, 31 : 48 - 48

← 1 2 3 4 5 →

HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number &lt;4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features

HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features